Hypnogen

Zolpidem, the active ingredient in Hypnogen, is a non‑benzodiazepine hypnotic presented as an oral tablet for oral use. It treats insomnia characterized by difficulty falling asleep in adult patients.

GNH USA supplies Hypnogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zolpidem is a short‑acting hypnotic used to manage sleep‑related disorders. - Insomnia (difficulty falling asleep): helps initiate sleep and reduce sleep latency. - Insomnia (early morning awakening): may extend total sleep time when awakening occurs too early. - Short‑term insomnia treatment: provides relief for transient sleep disturbances lasting a few weeks.

Adverse reactions can vary in frequency and severity.

Common Side Effects: - Drowsiness or fatigue - Dizziness or light‑headedness - Headache - Nausea or gastrointestinal discomfort - Unpleasant taste - Memory impairment or amnesia

Serious or Rare Side Effects: - Complex sleep‑related behaviours (e.g., sleepwalking, driving while asleep) - Allergic reactions (rash, swelling, anaphylaxis) - Depression or mood changes - Hallucinations or psychotic symptoms - Severe respiratory depression (especially with CNS depressants) - Suicidal thoughts or actions

Before prescribing Zolpidem, clinicians should consider several safety factors. - Assess sleep disorder: confirm diagnosis of insomnia and evaluate duration. - Concomitant CNS depressants: avoid or monitor use with alcohol, opioids, or other sedatives. - History of depression or suicidal ideation: monitor mental health closely. - Renal or hepatic impairment: dose adjustment may be required. - Pregnancy and lactation: use only if benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Zolpidem may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Opioids or CNS depressants: risk of profound sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antidepressants (e.g., fluoxetine, sertraline): may increase sedation. - Antihistamines or anticholinergics: may enhance drowsiness.